Application No.: 10/757,114 Docket No.: BB1167USDIV2

Page 5

## REMARKS

Applicants have cancelled all former claims, without prejudice or disclaimer and have substituted them with new Claims 12-22.

Claims 12-19 are now pending, with Claim 12 being the sole independent claim.

Claims 12-19 have been added. Support for the use of the term "recombinant" in Claim 16 is found at least in the paragraph beginning on line 10 of page 9 of the specification. Support for Claims 18-19 are found at least in Examples 4-5, pages 17-21 of the specification. No new matter has been added.

The specification has been amended at two locations to remove reference to the following URL: www.ncbi.nlm.nih.gov/BLAST/.

## RESPONSE TO RESTRICTION REQUIREMENT

In response to the Restriction Requirement in the Office Action mailed January 26, 2005, Applicants hereby elect, with traverse, Group I<sub>1</sub> (Claims 1-5, 10 and 11) drawn to a nucleic acid molecule encoding a sulfite reductase from *Oryza sativa*, and a host cell comprising said molecule, wherein said reductase is set forth by SEQ ID NO:2. Applicants submit that now pending Claims 12-19 are directed to Group I<sub>1</sub>.

Reconsideration of the Restriction Requirement is respectfully requested. Applicants respectfully submit that the subject matter of Group III<sub>1</sub>, Claim 7, which is drawn to a method of altering the level of expression of reductase in a host, may be properly rejoined with the polynucleotide claims of Group I<sub>1</sub> if such claims are found to be allowable.

Please charge any fees or credit any overpayment of fees which are required in connection herewith to Deposit Account No. 04-1928 (E. I. du Pont de Nemours and Company).

In view of the foregoing, allowance of the above-referenced application is respectfully requested.

Respectfully submitted,

Dawn S. Clarke

DAWN S. CLARK AGENT FOR APPLICANTS REGISTRATION NO. 42,420 TELEPHONE: 302-695-1080 FACSIMILE: 302-695-3125

Dated: march 17, 2005